Mirum Pharmaceuticals, Inc.
MIRM
Rangering i aksjer
#3281
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Aksjekurs
$82.58
Markedsverdi
$5.36B
Endring (1 dag)
3.05%
Endring (1 år)
12.31%
Land
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategori
Healthcare
EPS for Mirum Pharmaceuticals, Inc. (MIRM)
EPS per June 2026 TTM: $-14.56
Ifølge de siste økonomiske rapportene og aksjekursen til Mirum Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $-14.56. Ved slutten av 2023 hadde selskapet en EPS på $-4.00, en nedgang sammenlignet med EPS-en i 2022 som var $-4.01.
EPS-historikk for Mirum Pharmaceuticals, Inc. fra 2018 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
